Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 17/20 | 0.72 |
| ▸ | TCF7L2 | Q9NQB0 | 17/20 | 0.72 |
| ▸ | APP | P05067 | 2/20 | 0.63 |
| ▸ | PDE5A | O76074 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174731 | 0.90 | CTNNB1 (0.75) | CTNNB1TCF7L2 | |
| SCHEMBL3782735 | 0.88 | APP (0.81) | CTNNB1TCF7L2APPPDE5AMEN1 | |
| SCHEMBL4181792 | 0.85 | CTNNB1 (0.75) | CTNNB1TCF7L2 | |
| SCHEMBL4177771 | 0.85 | CTNNB1 (0.75) | CTNNB1TCF7L2 | |
| SCHEMBL4162854 | 0.84 | CTNNB1 (1.00) | CTNNB1TCF7L2 | |
| SCHEMBL3113122 | 0.79 | APP (1.00) | APPPDE5AMEN1LMNAMAPT | |
| SCHEMBL29388255 | 0.79 | APP (1.00) | APPPDE5AMEN1LMNAMAPT | |
| SCHEMBL3643055 | 0.78 | PDE5A (0.58) | CTNNB1TCF7L2APPPDE5AMEN1 | |
| SCHEMBL3121152 | 0.78 | APP (0.81) | APPPDE5AMEN1LMNAMAPT | |
| SCHEMBL4178562 | 0.78 | CTNNB1 (0.79) | CTNNB1TCF7L2APPPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004185-A1 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | TCF4, CTNNB1, TCF7 | CTNNB1 2/4885TCF7L2 4/4885APP 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.